We have applied our expertise in multivalency to discover product candidates and lead compounds in a number of therapeutic areas.

We believe that our lead product candidates have demonstrated in relevant preclinical models, potential advantages such as substantial increases in potency, duration of action and/or selectivity relative to existing medicines or potential medicines in late-stage clinical studies.

The table below summarizes the status of our most advanced product candidates for internal development or co-development. The table also includes the status of respiratory programs in which we have an economic interest that are being developed and commercialized by GSK pursuant to agreements with Theravance, Inc., now known as Innoviva, Inc.

Respiratory

YUPELRI® (revefenacin) inhalation solution: COPD

Collaborators: Mylan

Phase 1

Phase 2

Phase 3

Filed

Approved

TD-8326: Asthma

Phase 1

Gastrointestinal

TD-1473: Ulcerative Colitis

Collaborators: Janssen Biotech

Phase 1

Phase 2

TD-1473: Crohn’s Disease

Collaborators: Janssen Biotech

Phase 1

Phase 2

NEUROLOGICAL

Ampreloxetine (TD-9855): Symptomatic nOH

Phase 1

Phase 2

Phase 3

ECONOMIC INTEREST IN GSK-PARTNERED RESPIRATORY PROGRAMS *

TRELEGY ELLIPTA (FF/UMEC/VI): COPD

Collaborators: GSK & Innoviva, Inc.

Phase 1

Phase 2

Phase 3

Filed

Approved

TRELEGY ELLIPTA (FF/UMEC/VI): Asthma

Collaborators: GSK & Innoviva, Inc.

Phase 1

Phase 2

Phase 3

MABA, MABA/ICS (batefenterol, batefenterol/FF): COPD

Collaborators: GSK & Innoviva, Inc.

Phase 1

Phase 2

Other Economic Interests

Collaborators: Cumberland Pharmaceuticals

Phase 1

Phase 2

Phase 3

Filed

Approved

Velusetrag: Gastroparesis

Collaborators: Alfasigma

Phase 1

Phase 2

TD-8954 (TAK-954): POGD IV

Collaborators: Takeda

Phase 1

Phase 2

* The information regarding the Trelegy Ellipta and the MABA programs are based solely upon publicly available information and may not reflect the most recent developments under the programs.

Glossary of Defined Terms used in Table Above:

  • COPD: Chronic Obstructive Pulmonary Disease
  • cSSSI: Complicated Skin and Skin Structure Infections

  • FF: Fluticasone Furoate

  • HABP/VABP: Hospital‑Acquired and Ventilator‑Associated Bacterial Pneumonia

  • ICS: Inhaled Corticosteroid

  • IV: Intravenous

  • MABA: Bifunctional Muscarinic Antagonist‑Beta2 Agonist

  • nOH: Neurogenic Orthostatic Hypotension

  • POGD: Post-operative Gastrointestinal Dysfunction

  • UMEC: Umeclidinium

  • VI: Vilanterol

  • Status: The most advanced stage of clinical development that has been completed or is in process

  • Phase 1: Initial clinical safety testing into patients or healthy human volunteers, or studies directed toward understanding the mechanisms of action of the drug

  • Phase 2: Further clinical safety testing and preliminary efficacy testing in a limited patient population

  • Phase 3: Evaluation of clinical efficacy and safety within an expanded patient population

  • Filed: A marketing application has been submitted to a regulatory authority

  • Approved: Approved for marketing